CA2142981A1 - Vaccines against group c neisseria meningitidis - Google Patents

Vaccines against group c neisseria meningitidis

Info

Publication number
CA2142981A1
CA2142981A1 CA002142981A CA2142981A CA2142981A1 CA 2142981 A1 CA2142981 A1 CA 2142981A1 CA 002142981 A CA002142981 A CA 002142981A CA 2142981 A CA2142981 A CA 2142981A CA 2142981 A1 CA2142981 A1 CA 2142981A1
Authority
CA
Canada
Prior art keywords
gcmp
modified
conjugate
neisseria meningitidis
vaccines against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002142981A
Other languages
French (fr)
Other versions
CA2142981C (en
Inventor
Joseph Y. Tai
Lucjan J. J. Hronowski
Sharon Mates
Francis Michon
Harold Jennings
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/938,367 external-priority patent/US5425946A/en
Application filed by Individual filed Critical Individual
Publication of CA2142981A1 publication Critical patent/CA2142981A1/en
Application granted granted Critical
Publication of CA2142981C publication Critical patent/CA2142981C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

An immunogenic conjugate comprising a modified group C meningococcal polysaccharide (GCMP) coupled to a carrier molecule. The GCMP is modified by O-deacetylation to a varying extent. This modified GCMP conjugate stimulates a strong im-munogenic response. The antiserum, produced by immunization with this conjugate, is cross-reactive with the native polysaccha-ride. In addition, these antisera elicit a class of antibodies that have potent bactericidal activity.
CA002142981A 1992-08-31 1993-08-30 Vaccines against group c neisseria meningitidis Expired - Lifetime CA2142981C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US07/938,367 US5425946A (en) 1992-08-31 1992-08-31 Vaccines against group C Neisseria meningitidis
US07/938,367 1992-08-31
US6450193A 1993-05-19 1993-05-19
US08/064,501 1993-05-19
PCT/US1993/008155 WO1994005325A1 (en) 1992-08-31 1993-08-30 Vaccines against group c neisseria meningitidis

Publications (2)

Publication Number Publication Date
CA2142981A1 true CA2142981A1 (en) 1994-03-17
CA2142981C CA2142981C (en) 2007-10-23

Family

ID=26744584

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002142981A Expired - Lifetime CA2142981C (en) 1992-08-31 1993-08-30 Vaccines against group c neisseria meningitidis

Country Status (12)

Country Link
EP (1) EP0658118B1 (en)
JP (2) JP4097691B2 (en)
AT (1) ATE212233T1 (en)
AU (1) AU4841693A (en)
CA (1) CA2142981C (en)
DE (1) DE69331495T2 (en)
DK (1) DK0658118T3 (en)
ES (1) ES2171418T3 (en)
NO (1) NO323616B1 (en)
PL (1) PL175595B1 (en)
PT (1) PT658118E (en)
WO (1) WO1994005325A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780606A (en) * 1995-06-07 1998-07-14 Connaught Laboratories Limited Neisseria meningitidis capsular polysaccharide conjugates
GB9713156D0 (en) * 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
US6413520B1 (en) 1997-06-24 2002-07-02 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
EP1278548A2 (en) 2000-04-18 2003-01-29 Endobiologics, Incorporated Lipopolysaccharide-conjugate vaccine for sepsis treatment
US7749511B2 (en) 2000-04-18 2010-07-06 Endobiologics, Incorporated Anti-sepsis conjugate vaccine
EA006947B1 (en) * 2001-01-23 2006-06-30 Авентис Пастер Multivalent meningococcal polysaccharide-protein conjugate vaccine
CA2530364C (en) * 2003-06-23 2014-03-18 Baxter International Inc. Vaccines against group y neisseria meningitidis and meningococcal combinations thereof
ATE506963T1 (en) 2003-10-02 2011-05-15 Novartis Vaccines & Diagnostic COMBINATION VACCINES AGAINST MENINGITIS
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
BRPI0510315A (en) 2004-04-30 2007-10-16 Chiron Srl integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
NZ572054A (en) 2006-03-22 2011-12-22 Novartis Ag Regimens for immunisation with meningococcal conjugates
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
JP5637848B2 (en) 2007-06-04 2014-12-10 ノバルティス アーゲー Formulation of meningitis vaccine
JP5701058B2 (en) 2007-10-19 2015-04-15 ノバルティス アーゲー Meningococcal vaccine formulation
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
AU2009329193A1 (en) 2008-12-17 2011-07-14 Novartis Ag Meningococcal vaccines including hemoglobin receptor
WO2010074991A1 (en) * 2008-12-22 2010-07-01 Children's Hospital & Research Center At Oakland Ex-vivo passive protection bacteremia assay
NZ595234A (en) 2009-03-24 2013-12-20 Novartis Ag Adjuvanting meningococcal factor h binding protein
CA2756533A1 (en) 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
EP2585106A1 (en) 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
EP2680885B8 (en) 2011-03-02 2018-07-25 GlaxoSmithKline Biologicals SA Combination vaccines with lower doses of antigen and/or adjuvant
WO2013009564A1 (en) 2011-07-08 2013-01-17 Novartis Ag Tyrosine ligation process
AU2012335208B2 (en) 2011-11-07 2017-08-31 Glaxosmithkline Biologicals S.A. Carrier molecule comprising a spr0096 and a spr2021 antigen
US10596246B2 (en) 2011-12-29 2020-03-24 Glaxosmithkline Biological Sa Adjuvanted combinations of meningococcal factor H binding proteins
CN104159603A (en) 2012-03-08 2014-11-19 诺华股份有限公司 Combination vaccines with tlr4 agonists
RU2015106930A (en) 2012-09-06 2016-10-20 Новартис Аг COMBINED VACCINES WITH THE MENINGOCOCC SEROGRAPH B AND K / D / S
EP2934574A1 (en) 2012-12-18 2015-10-28 GlaxoSmithKline Biologicals SA Conjugates for protecting against diphtheria and/or tetanus
CN105593238B (en) 2013-07-11 2020-09-08 诺华股份有限公司 Lysine-specific chemoenzymatic protein modification using microbial transglutaminase
MY186874A (en) * 2014-02-25 2021-08-26 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd A novel downstream process for purifying polysaccharides
JP7104027B2 (en) 2016-09-02 2022-07-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Vaccine against gonorrhea

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5097020A (en) * 1983-07-05 1992-03-17 The University Of Rochester Immunogenic conjugates
FR2682388B1 (en) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc PROCESS FOR THE PREPARATION OF AN OLIGOSIDE BY DEPOLYMERIZATION OF A POLYOSIDE DERIVED FROM A PATHOGENIC AGENT, OLIGOSIDE THUS OBTAINED AND ITS USE IN PARTICULAR AS A VACCINE AGENT.

Also Published As

Publication number Publication date
DE69331495T2 (en) 2002-10-31
WO1994005325A1 (en) 1994-03-17
EP0658118A1 (en) 1995-06-21
JPH08500607A (en) 1996-01-23
PL307745A1 (en) 1995-06-12
PL175595B1 (en) 1999-01-29
JP2008044955A (en) 2008-02-28
DK0658118T3 (en) 2002-05-06
EP0658118A4 (en) 1995-09-13
NO950739D0 (en) 1995-02-27
JP4097691B2 (en) 2008-06-11
ES2171418T3 (en) 2002-09-16
NO323616B1 (en) 2007-06-18
NO950739L (en) 1995-04-26
CA2142981C (en) 2007-10-23
AU4841693A (en) 1994-03-29
PT658118E (en) 2002-05-31
ATE212233T1 (en) 2002-02-15
DE69331495D1 (en) 2002-03-14
EP0658118B1 (en) 2002-01-23

Similar Documents

Publication Publication Date Title
CA2142981A1 (en) Vaccines against group c neisseria meningitidis
Chu et al. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates
Schneerson et al. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates.
RU2009134033A (en) LIQUID VACCINES FOR MULTIPLE SERIES OF MENINGOCOCCUS
WO1990006696A3 (en) Meningococcal class 1 outer-membrane protein vaccine
ES8707861A1 (en) Immunogenic conjugates of E. coli LT-B enterotoxin subunit and capsular polymers.
EP0117783A3 (en) Coupled haemophilus inflenzae type b vaccine
EP2368575A3 (en) Dry formulation for transcutaneous immunization
EP0655929A1 (en) Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
NO974727L (en) Immunogenic and immunostimulatory oligosaccharide compositions and methods for their preparation
EA199700419A1 (en) VACCINE COMPOSITION CONTAINING POLYRIBOSILRIBITOLPHOSPHATE AND METHOD FOR ITS PREPARATION
ES8608883A1 (en) Conjugates of haptenes and muramyl peptides having an immunogenic activity, and compositions containing them.
CA2277141A1 (en) Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this procedure
DK341679A (en) VACCINE AGAINST DRAFT COOKIES AND PROCEDURES FOR PRODUCING THEREOF
EP0326111A3 (en) Peptide derivatives rendered immunogenic when administered with alum as an adjuvant
Eskola et al. Experience in Finland with Haemophilus influenzae type b vaccines
HU9303028D0 (en) Combined pediatric vaccine with improved immunogenecity in the components regard
ROBBINS et al. Haemophilus influenzae type b: the search for a vaccine
NO913131L (en) IMMUNOGENIC CONJUGATES OF NON-TOXIC OLIGOSACCHARIDE FROM TABLE TELL PERTUSSIS LIPOOLYSACCHARIDE.
CA2004206A1 (en) Method for preparing pertussis toxin toxoid
Michon et al. Combination conjugate vaccines against multiple serotypes of group B streptococci
CA2090005A1 (en) Cross-reactive influenza a immunization
Paniagua-Solis et al. Predicted epitopes of Salmonella typhi OmpC porin are exposed on the bacterial surface
Guo et al. Studies on meningococcal polysaccharide-tetanus toxoid conjugates.
MÄKELÄ et al. Vaccines for Haemophilus influenzae type b as models for an otitis vaccine

Legal Events

Date Code Title Description
EEER Examination request